Elisa Sottotetti

Medicine & Life Sciences

1. Circulating Tumor DNA 100%
2. Colorectal Neoplasms 65%
3. DNA Fingerprinting 57%
4. Alleles 36%
5. Progression-Free Survival 35%
6. Confidence Intervals 29%
7. Survival 24%
8. Gene Frequency 22%
9. Renal Cell Carcinoma 22%
10. Tumor Burden 22%
11. Non-Small Cell Lung Carcinoma 21%
12. Mutation 21%
13. Neoplasms 20%
14. cabozantinib 18%
15. mesothelin 18%
16. Prospective Studies 18%
17. pazopanib 17%
18. Osteopontin 16%
19. Vinorelbine 15%
20. Anaplastic Lymphoma Kinase 15%
21. Panitumumab 15%
22. Clinical Decision Support Systems 15%
23. Methylenetetrahydrofolate Reductase (NADPH2) 14%
24. Severe Acute Respiratory Syndrome 14%
25. High-Throughput Nucleotide Sequencing 14%
26. Factor V 14%
27. Porphyrins 14%
28. Response Evaluation Criteria in Solid Tumors 14%
29. Coronavirus 14%
30. Liquid Biopsy 14%
31. Circulating Neoplastic Cells 14%
32. Malignant Mesothelioma 14%
33. Medical Oncology 13%
34. Drug Therapy 13%
35. Prothrombin 13%
36. Datasets 13%
37. Thromboembolism 13%
38. Plasminogen Activator Inhibitor 1 13%
39. Bevacizumab 12%
40. Castration 12%
41. Platinum 12%
42. Immunotherapy 12%
43. Humoral Immunity 12%
44. Bone Remodeling 11%
45. Parathyroid Hormone 11%
46. ROC Curve 10%
47. MicroRNAs 9%
48. Fluorescence 9%
49. Vaccination 9%
50. Prostatic Neoplasms 9%